LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

A new study adds to evidence which suggests treating breast cancer patients with sodium channel blockers could be a promising future treatment to prevent the spread of cancer during the gap between ...

Blockade of voltage-gated sodium channels (NaChs) in pancreatic α cells has anti-diabetic effects, according to research published online May 8 in Diabetes. Arvinder K. Dhalla, Ph.D., of Gilead ...

Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...

South Korea’s SK Biopharmaceuticals Co. Ltd. and Shanghai-based Ignis Therapeutic Co. Ltd. signed a ₩804 billion (US$58 million) licensing deal on April 18, granting the latter global rights to a ...

Inspired by the natural bonding between a class of potent local anesthetics called site-1 sodium channel blockers (S1SCBs) and peptide sequences on the sodium channel in the nerve cell membrane, ...

A novel, investigational NaV1.8 sodium channel blocker known as VX-548 reduced acute pain after abdominoplasty or bunionectomy at the highest dose, but not at lower doses, two phase II trials showed.

Last year, the U.S. Food and Drug Administration approved a new drug — suzetrigine — the first truly new kind of painkiller ...

Topline results from the ASPIRE Phase 2b study expected in mid-2026 with operating runway through 2027Series B extension was led by Arkin Bio Capital and Monograph Capital, with participation from ...